Phosphate Microvascular Study
The Effects of Phosphate on Microvascular Function
Elevated phosphate concentrations in the blood have been associated with multiple negative health outcomes in patients with chronic kidney disease as well as in the general population. These negative outcomes include an increased risk of vascular complications like heart attack and stroke. While complications like heart attack and stroke reflect obstructive disease in large blood vessels, recent evidence suggests that elevated phosphate concentrations may first lead to disease in small blood vessels.
This single site clinical trial will randomize 20 veterans with end stage renal disease on hemodialysis to either a phosphate binder or placebo and evaluated for changes in their microvascular function using laser-Doppler flowmtery and nail-fold capillaroscopy.
研究概览
详细说明
Project Background: Recent studies have suggested that increased serum phosphate and phosphate intake may acute impair microvascular blood flow. However, this has never been directly tested using imaging techniques that directly measure microvascular flow. The end-stage renal disease population on hemodialysis at the VA San Diego is an ideal population to evaluate this effect.
Project Question: Does reduction of serum phosphate through the use of a phosphate binder (lanthanum carbonate) increase microvascular blood flow in persons with ESRD? Project Methods: The investigators propose a 4 week, randomized, double-blinded, placebo controlled, single-center, crossover trial. Participants will have their microvascular function assessed at the baseline of the study using laser-Doppler flowmetry and nail-fold capillaroscopy. They will then be randomized to either lanthanum carbonate or placebo for 2 weeks. Microvascular measurements will be repeated at the end of the 2 week period. Participants will then cross-over to the other study arm. After 2 weeks in the other study arm, they will have microvascular measurements repeated and the trial will then be complete. The primary outcome of the study will be the % change in skin blood flow after heating from 31 degrees Celsius to 44 degrees Celsius. This will be compared within each individual after they complete each arm of the study. Changes seen on nail-fold capillaroscopy, acceptability, safety, and adherence will be key secondary outcomes.
研究类型
注册 (预期的)
阶段
- 不适用
联系人和位置
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Diagnosis of ESRD on hemodialysis (HD) for >90 days.
- Age >21.
- Capacity to understand and sign informed consent as assess by principal investigator.
- On a phosphate binder with stable dose for >2 weeks.
- Serum phosphate at screening visit of <7.0.
Exclusion Criteria:
- Pregnancy.
- Actively breastfeeding.
- Use of oral contraceptives.
- Inability to take oral medications.
- History of medication non-compliance as assessed by the treating physician.
- Patients currently enrolled in another trial.
- Planned or expected surgical procedure during study period.
- Planned or expected hospitalization during study period.
- Corrected serum calcium greater than 10.2 mg/dl.
- Serum intact PTH >1000 pg/ml
- Albumin < 3 g/dl.
- Allergy or intolerance to lanthanum carbonate.
- Principal investigator deems patient to be unsuitable.
- Non-English speaking persons. (Study performed at VA, therefore do not anticipate this represents a significant portion of the population).
学习计划
研究是如何设计的?
设计细节
- 主要用途:诊断
- 分配:随机化
- 介入模型:交叉作业
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
无干预:Standard
Participants will have their hyperphosphatemia managed with lanthanum carbonate 1 g with meals and 500 mg with snacks as per typical care, for 2 weeks.
|
|
|
安慰剂比较:Intervention
Participants will take a placebo instead of standard care with a phosphate binder, for 2 weeks.
|
In this trial, placebo represents the intervention and not the control.
Standard therapy for hyperphosphatemia in end-stage renal disease includes treatment with a phosphate binder.
In this trial the intervention will be to withhold the phosphate binder and use placebo instead.
In this way the effect of a higher serum phosphate can be evaluated.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
% Change in flux of blood after skin heating to 44 C as measured using laser-Doppler flowmtery.
大体时间:Performed at initial study visit, at the end of the first arm of the study (Day 14) and again at the end of the second arm of the study (Day 28)
|
Flux of blood through skin will be measured using a Perimed PF5000.
This will be performed at baseline in a temperature controlled room.
Baseline skin measurements will be made at 31C.
Skin will then be heated to 44 C. The percent change will be the outcome.
This outcome will be compared within each person at the conclusion of each arm.
Measurements will all be made on the Monday or Tuesday, the day of the participant's first dialysis treatment of the week.
Measurements will be made prior to dialysis.
|
Performed at initial study visit, at the end of the first arm of the study (Day 14) and again at the end of the second arm of the study (Day 28)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in capillary count seen post occlusion from pre occlusion, as determined by nail-fold capillaroscopy.
大体时间:Performed at initial study visit, at the end of the first arm of the study (Day 14) and again at the end of the second arm of the study (Day 28)
|
Participants will undergo nail fold capillaroscopy using a CapiScope (KK Technology, Honiton United Kingdom) at baseline and then at the end of each treatment arm.
Using a capillarascope a capillary count will be made.
After measurement a BP cuff will be inflated to 200 mm Hg occlude flow to a single digit for 1 minute.
30 sec after release the count will be made again.
This change will be compared within individuals between measurements made at the completion of each arm in the study.
Measurements will all be made on the Monday or Tuesday, the day of the participant's first dialysis treatment of the week.
Measurements will be made prior to dialysis.
Values at the end of each treatment arm will be compared.
|
Performed at initial study visit, at the end of the first arm of the study (Day 14) and again at the end of the second arm of the study (Day 28)
|
合作者和调查者
出版物和有用的链接
一般刊物
- O'Seaghdha CM, Hwang SJ, Muntner P, Melamed ML, Fox CS. Serum phosphorus predicts incident chronic kidney disease and end-stage renal disease. Nephrol Dial Transplant. 2011 Sep;26(9):2885-90. doi: 10.1093/ndt/gfq808. Epub 2011 Feb 3.
- Thambyrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, Townend JN. Abnormalities of endothelial function in patients with predialysis renal failure. Heart. 2000 Feb;83(2):205-9. doi: 10.1136/heart.83.2.205.
- Stevens KK, Denby L, Patel RK, Mark PB, Kettlewell S, Smith GL, Clancy MJ, Delles C, Jardine AG. Deleterious effects of phosphate on vascular and endothelial function via disruption to the nitric oxide pathway. Nephrol Dial Transplant. 2017 Oct 1;32(10):1617-1627. doi: 10.1093/ndt/gfw252.
研究记录日期
研究主要日期
学习开始 (预期的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- VAH170095
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
IPD 共享支持信息类型
- 研究协议
- 统计分析计划 (SAP)
- 知情同意书 (ICF)
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.